Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication

 
• By Sue Sutter
  
Risk benefit
Lexicon's sotagliflozin in type 1 diabetes patients with chronic kidney disease failed the adcomm's risk-benefit test. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Geography